Bayer/J&J's Xarelto Gets Advisory Cmte. Endorsement In A-Fib, But Not First-Line Use
This article was originally published in The Pink Sheet Daily
Cardiovascular and Renal Drugs Advisory Committee votes 9-2, with one abstention, in favor of approval, but more than half the panelists said the indication should be limited to patients who fail other anticoagulant therapy.
You may also be interested in...
As Daiichi’s experience suggests, sponsors of later-in-class products may face unfavorable efficacy comparisons to their earlier-approved brethren and challenges in qualifying for a priority review; however, risk management obligations may be less burdensome than for first-in-class products.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.